- Home
- AOMR vs FULC Comparison
AOMR vs FULC Comparison
Compare AOMR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- FULC
- Stock Information
- Founded
- AOMR 2018
- FULC 2015
- Country
- AOMR United States
- FULC United States
- Employees
- AOMR N/A
- FULC N/A
- Industry
- AOMR Real Estate Investment Trusts
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- AOMR Real Estate
- FULC Health Care
- Exchange
- AOMR Nasdaq
- FULC Nasdaq
- Market Cap
- AOMR 219.8M
- FULC 221.5M
- IPO Year
- AOMR 2021
- FULC 2019
- Fundamental
- Price
- AOMR $9.12
- FULC $4.34
- Analyst Decision
- AOMR Buy
- FULC Hold
- Analyst Count
- AOMR 6
- FULC 10
- Target Price
- AOMR $12.10
- FULC $7.44
- AVG Volume (30 Days)
- AOMR 85.8K
- FULC 872.0K
- Earning Date
- AOMR 11-06-2024
- FULC 11-13-2024
- Dividend Yield
- AOMR 14.04%
- FULC N/A
- EPS Growth
- AOMR N/A
- FULC N/A
- EPS
- AOMR 2.91
- FULC N/A
- Revenue
- AOMR $94,441,000.00
- FULC $80,871,000.00
- Revenue This Year
- AOMR N/A
- FULC $2,820.53
- Revenue Next Year
- AOMR $31.91
- FULC N/A
- P/E Ratio
- AOMR $3.13
- FULC N/A
- Revenue Growth
- AOMR 455.18
- FULC 2987.86
- 52 Week Low
- AOMR $8.88
- FULC $2.86
- 52 Week High
- AOMR $13.32
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- AOMR 38.33
- FULC 63.62
- Support Level
- AOMR $9.22
- FULC $3.94
- Resistance Level
- AOMR $9.74
- FULC $4.64
- Average True Range (ATR)
- AOMR 0.21
- FULC 0.33
- MACD
- AOMR -0.02
- FULC 0.08
- Stochastic Oscillator
- AOMR 18.96
- FULC 81.90
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.